Geneva, March 20 -- International Clinical Trials Registry received information related to the study (KCT0011646) titled 'Regorafenib after treatment failure of first line immune checkpoint inhibitor treatment in advanced hepatocellular carcinoma patients' on Feb. 25.
Study Type: Interventional Study
Study Design:
Primary Purpose : Treatment, Intervention Model : Single Group, Blinding/Masking : Open, Allocation : Not Applicable
Primary Sponsor: Asan Medical Center
Condition:
Neoplasms
Intervention:
Drug : All study participants will receive regorafenib after providing written informed consent. Regorafenib will be administered orally at a dose of 120 mg once daily at the same time each day, after a meal with water, on a schedule ...